Nektar Therapeutics (NKTR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nektar Therapeutics (NKTR) Earnings: Report Dates and Results
Nektar Therapeutics (NKTR) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Nektar Therapeutics reported EPS of -$1.63, above the -$2.16 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NKTR has an expected report date of Mar 10, 2027.
NKTR Earnings Call
The latest NKTR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, NKTR beat 29, missed 10 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $9.39M, down 20.4% from $11.79M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.63 | -$2.16 | -$3.07 - -$1.71 | +24.54% | Beat | N/A | 15 | 2 up, 0 down | Nov 12, 2026 | $9.39M |
| Jun 30, 2026 | -$1.23 | -$2.06 | -$2.74 - -$1.72 | +40.29% | Beat | N/A | 4 | 2 up, 0 down | Aug 13, 2026 | $10.13M |
| Mar 31, 2026 | -$1.78 | -$1.48 | -$1.83 - -$1.22 | -20.27% | Miss | N/A | 4 | N/A | May 7, 2026 | $10.86M |
| Dec 31, 2025 | -$1.78 | -$2.47 | N/A | +28.05% | Beat | N/A | 2 | 0 up, 0 down | Mar 12, 2026 | $21.81M |
| Sep 30, 2025 | -$1.87 | -$2.79 | -$3.23 - -$2.32 | +32.97% | Beat | N/A | 3 | 1 up, 0 down | Nov 6, 2025 | $11.79M |
| Jun 30, 2025 | -$2.95 | -$3.13 | -$3.43 - -$2.81 | +5.75% | Beat | N/A | 2 | 0 up, 1 down | Aug 7, 2025 | $11.18M |
| Mar 31, 2025 | -$3.61 | -$2.82 | -$3.15 - -$2.47 | -28.01% | Miss | N/A | 3 | 1 up, 0 down | May 8, 2025 | $10.46M |
| Dec 31, 2024 | -$0.15 | -$0.13 | N/A | -15.38% | Miss | N/A | 2 | 1 up, 0 down | Mar 12, 2025 | $29.18M |
| Sep 30, 2024 | -$2.65 | -$3.09 | -$3.90 - -$2.40 | +14.24% | Beat | N/A | 7 | 0 up, 0 down | Nov 7, 2024 | $24.12M |
| Jun 30, 2024 | -$2.81 | -$3.01 | -$3.60 - -$2.55 | +6.64% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | $23.49M |
| Mar 31, 2024 | -$2.76 | -$3.07 | -$3.30 - -$2.55 | +10.10% | Beat | N/A | 3 | 0 up, 0 down | May 9, 2024 | $21.64M |
| Dec 31, 2023 | -$0.22 | -$0.21 | -$0.33 - -$0.15 | -4.76% | Miss | N/A | 5 | 0 up, 0 down | Mar 4, 2024 | $23.89M |
| Sep 30, 2023 | -$2.85 | -$2.40 | -$4.05 - -$2.25 | -18.75% | Miss | N/A | 7 | 1 up, 0 down | Nov 7, 2023 | $24.14M |
| Jun 30, 2023 | -$4.05 | -$3.30 | -$6.30 - -$3.30 | -22.73% | Miss | N/A | 8 | 0 up, 0 down | Aug 8, 2023 | $20.50M |
| Mar 31, 2023 | -$3.75 | -$3.59 | -$4.95 - -$2.40 | -4.46% | Miss | N/A | 7 | 0 up, 0 down | May 9, 2023 | $21.59M |
| Dec 31, 2022 | -$0.32 | -$0.45 | -$0.55 - -$0.24 | +28.89% | Beat | N/A | 10 | 1 up, 0 down | Feb 28, 2023 | $22.02M |
| Sep 30, 2022 | -$4.65 | -$6.54 | -$9.90 - -$4.35 | +28.90% | Beat | N/A | 10 | 0 up, 0 down | Nov 3, 2022 | $23.63M |
| Jun 30, 2022 | -$12.75 | -$15.25 | -$17.39 - -$9.45 | +16.39% | Beat | N/A | 10 | 0 up, 0 down | Aug 4, 2022 | $21.59M |
| Mar 31, 2022 | -$7.35 | -$10.01 | -$13.34 - -$7.35 | +26.57% | Beat | N/A | 11 | 5 up, 2 down | May 5, 2022 | $24.82M |
| Dec 31, 2021 | -$0.79 | -$0.81 | -$0.89 - -$0.71 | +2.47% | Beat | N/A | 13 | 1 up, 0 down | Feb 28, 2022 | $25.01M |
| Sep 30, 2021 | -$10.50 | -$12.09 | -$13.19 - -$10.94 | +13.15% | Beat | N/A | 11 | 3 up, 0 down | Nov 4, 2021 | $24.92M |
| Jun 30, 2021 | -$10.35 | -$10.98 | -$11.69 - -$10.04 | +5.74% | Beat | N/A | 12 | N/A | Aug 5, 2021 | $28.33M |
| Mar 31, 2021 | -$10.20 | -$10.90 | -$12.59 - -$8.70 | +6.42% | Beat | N/A | 10 | N/A | May 6, 2021 | $23.65M |
| Dec 31, 2020 | -$0.65 | -$0.68 | -$0.80 - $0.04 | +4.41% | Beat | N/A | 13 | N/A | Feb 25, 2021 | $23.46M |
| Sep 30, 2020 | -$9.15 | -$11.28 | -$12.59 - -$7.65 | +18.88% | Beat | N/A | 13 | N/A | Nov 5, 2020 | $30.03M |
| Jun 30, 2020 | -$6.75 | -$10.32 | -$11.24 - -$8.85 | +34.59% | Beat | N/A | 14 | N/A | Aug 6, 2020 | $48.85M |
| Mar 31, 2020 | -$0.53 | -$0.77 | -$0.88 - -$0.43 | +31.17% | Beat | N/A | 14 | N/A | May 7, 2020 | $50.57M |
| Dec 31, 2019 | -$9.60 | -$10.30 | -$11.39 - -$7.95 | +6.80% | Beat | N/A | 13 | N/A | Feb 27, 2020 | $33.86M |
| Sep 30, 2019 | -$8.40 | -$10.83 | -$12.29 - -$9.75 | +22.44% | Beat | N/A | 13 | N/A | Nov 6, 2019 | $29.22M |
| Jun 30, 2019 | -$9.45 | -$12.00 | -$12.89 - -$11.24 | +21.25% | Beat | -111.8% | 11 | N/A | Aug 8, 2019 | $23.32M |
| Mar 31, 2019 | -$10.20 | -$11.34 | -$12.29 - -$5.10 | +10.05% | Beat | N/A | 11 | N/A | May 8, 2019 | $28.22M |
| Dec 31, 2018 | -$0.57 | -$0.65 | -$0.80 - $0.65 | +12.31% | Beat | N/A | 11 | N/A | Feb 28, 2019 | $39.83M |
| Sep 30, 2018 | -$8.40 | -$9.46 | -$10.94 - -$7.80 | +11.21% | Beat | -251.4% | 8 | N/A | Nov 7, 2018 | $27.76M |
| Jun 30, 2018 | $79.95 | $79.30 | $64.77 - $88.31 | +0.82% | Beat | N/A | 10 | N/A | Aug 8, 2018 | $1.09B |
| Mar 31, 2018 | -$9.00 | -$8.20 | -$10.49 - $82.16 | -9.76% | Miss | N/A | 10 | N/A | May 10, 2018 | $38.02M |
| Dec 31, 2017 | -$0.11 | -$0.35 | -$0.43 - -$0.26 | +68.57% | Beat | N/A | 7 | N/A | Mar 1, 2018 | $95.47M |
| Sep 30, 2017 | $5.55 | $3.36 | -$3.00 - $4.05 | +65.18% | Beat | N/A | 7 | N/A | Nov 7, 2017 | $152.93M |
| Jun 30, 2017 | -$5.85 | -$5.45 | -$6.30 - -$4.05 | -7.34% | Miss | N/A | 7 | N/A | Aug 8, 2017 | $34.59M |
| Mar 31, 2017 | -$0.42 | -$0.42 | N/A | 0.00% | In line | N/A | N/A | N/A | May 9, 2017 | $24.73M |
| Dec 31, 2016 | -$4.20 | -$4.01 | N/A | -4.74% | Miss | N/A | N/A | N/A | Mar 1, 2017 | $37.45M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$10.21, after -$8.37 the year before. It was -$16.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$10.21 | N/A |
| Dec 31, 2024 | -$8.37 | N/A |
| Dec 31, 2023 | -$10.87 | N/A |
| Dec 31, 2022 | -$25.07 | N/A |
| Dec 31, 2021 | -$31.84 | N/A |
| Dec 31, 2020 | -$17.08 | N/A |
| Dec 31, 2019 | -$37.65 | -160.7% |
| Dec 31, 2018 | $61.98 | N/A |
| Dec 31, 2017 | -$0.83 | N/A |
| Dec 31, 2016 | -$16.50 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,678 | 18 | |
| 2026Q2 | Jun 30, 2026 | 6,442 | 16 | |
| 2026Q1 | Mar 31, 2026 | 6,668 | 16 | |
| 2025Q4 | Dec 31, 2025 | 7,225 | 14 | |
| 2025Q3 | Sep 30, 2025 | 6,552 | 13 | |
| 2025Q2 | Jun 30, 2025 | 7,415 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,314 | 13 | |
| 2024Q3 | Sep 30, 2024 | 5,849 | 12 |
2026Q3 Earnings Call
Opening remarks
Vivian Wu Investor Relations Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today. On today's call, you will hear from Howard Robin, our President and Chief Executive Officer; Dr. Mary Tagliaferri, our Chief Medical Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Linda Rubinstein, our Chief Financial Officer. Before we begin, I would like to remind you that we will be making forward-looking statements regarding our business, including statements related to the therapeutic and commercial potential and development plans for rezpegaldesleukin, the timing and execution of clinical trials, expectations for clinical data and regulatory filings, potential strategic partnering activities, financial guidance, and other statements regarding the future of our business. Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult to predict, many of which are outside of our control. For a discussion of these risks and uncertainties, please refer to our filings with the SEC, including our most recent Form 10-K and subsequent filings. We undertake no obligation to update these forward-looking statements except as required by law. A live webcast and replay of this call will be available on the Investor Relations section of our website at nektar.com. With that, I'll turn the call over to Howard.
Howard W. Robin President and Chief Executive Officer Thank you, Vivian. Thank you to everyone for joining us this afternoon. Q3 was a transformative quarter for Nektar as we advanced REZPEG into phase III studies. Building on its compelling phase II results across two key immune dermatology indications, we initiated a comprehensive phase III plan for REZPEG in both atopic dermatitis and alopecia areata. Our global phase III studies in atopic dermatitis have started, and our phase III study in alopecia areata is on track to start in December, earlier than was originally planned. As we said last quarter, we anticipate our first top-line data readouts for the atopic dermatitis studies will be in the summer of 2028. In the U.S. alone, over 31 million people are estimated to have eczema. The U.S. market for treatments for this chronic disorder is expected to grow to over $30 billion by 2033. Now, in spite of a number of approved systemic therapies to treat patients with moderate to severe atopic dermatitis, only 1 in 4 patients today receive a systemic treatment. Atopic dermatitis is a highly heterogeneous disease, meaning the biology driving the underlying disease state can be complex and can vary significantly from one patient to another. The current approved biologics target one single inflammatory pathway, specifically the type 2 inflammatory pathway, and mostly through IL-13 cytokine blocking.
Frequently Asked Questions About NKTR
When is Nektar Therapeutics's next earnings date?
Nektar Therapeutics's next earnings report is expected for Mar 10, 2027.
Did NKTR beat earnings estimates last quarter?
Yes. Nektar Therapeutics reported EPS of -$1.63 for the quarter ended Sep 30, 2026, above the -$2.16 estimate, a 24.54% surprise.
What EPS do analysts expect from NKTR next quarter?
The consensus EPS estimate for Nektar Therapeutics for the quarter ending Dec 31, 2026 is -$2.53 from 17 analysts, with estimates from -$3.43 to -$1.79.
How often does NKTR beat earnings estimates?
Nektar Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +8.49%.
NKTR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors